title: Bevacizumab in macular edema: functional and anatomic changes in a prospective case series.
abstract: OBJECTIVE
  To evaluate the early rate of change of best-corrected visual acuity (BCVA), central retinal sensitivity, neuroretinal and choroidal thickness in patients with macular edema after 1.25 mg/0.05 ml intravitreal bevacizumab (Avastin; Genentech, Inc., South San Francisco, CA).
  
  
  METHODS
  A prospective, nonrandomized, interventional study. Thirty-seven consecutive eyes with macular edema were included in the study. For all eyes, BCVA, central retinochoroidal thickness at standardized A-scan, central retinal thickness, and central retinal sensitivity recorded with a spectral scanning laser ophthalmoscope optical coherence tomography/microperimeter device were evaluated at baseline and 7, 15, 30, 37, 45, and 60 days after initial treatment. All patients received 2 intravitreal bevacizumab injections at 1-month interval.
  
  
  RESULTS
  A significant although not related improvement of BCVA and retinal sensitivity was seen after 1 month and 2 months of follow-up. Anatomic improvement only involved the neuroretina, although significant changes of central choroidal thickness were not detected.
  
  
  CONCLUSIONS
  Intravitreal bevacizumab for macular edema determines significant early functional and anatomic improvements.
authors: Eye Department, University Federico II, Naples, Italy. raifor@hotmail.com
authors: Raimondo
authors: R
authors: Forte
authors: Gilda
authors: G
authors: Cennamo
authors: Elisabetta Chiariello
authors: EC
authors: Vecchio
authors: Raffaele
authors: R
authors: Tenore
authors: Bernardino
authors: B
authors: Aufiero
authors: Giuseppe
authors: G
authors: de Crecchio
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D002829:Choroid / Q000000981:diagnostic imaging / Q000473:pathology; D005260:Female; D006801:Humans; D008269:Macular Edema / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D008297:Male; D018613:Microscopy, Confocal; D008875:Middle Aged; D009887:Ophthalmoscopy / Q000379:methods; D011446:Prospective Studies; D012160:Retina / Q000000981:diagnostic imaging / Q000473:pathology / Q000503:physiopathology; D012164:Retinal Diseases / Q000150:complications; D041623:Tomography, Optical Coherence / Q000379:methods; D016896:Treatment Outcome; D014463:Ultrasonography; D014792:Visual Acuity / Q000187:drug effects; D058609:Visual Field Tests / Q000379:methods
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab